nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP2E1—Dacarbazine—muscle cancer	0.171	0.207	CbGbCtD
Ondansetron—CYP1A2—Dacarbazine—muscle cancer	0.0987	0.12	CbGbCtD
Ondansetron—CYP3A7—Vincristine—muscle cancer	0.0944	0.115	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.0944	0.115	CbGbCtD
Ondansetron—CYP2E1—Etoposide—muscle cancer	0.0835	0.101	CbGbCtD
Ondansetron—CYP3A5—Vincristine—muscle cancer	0.0708	0.086	CbGbCtD
Ondansetron—CYP3A5—Etoposide—muscle cancer	0.0649	0.0788	CbGbCtD
Ondansetron—CYP1A2—Etoposide—muscle cancer	0.0483	0.0587	CbGbCtD
Ondansetron—CYP3A4—Vincristine—muscle cancer	0.0276	0.0335	CbGbCtD
Ondansetron—CYP2D6—Doxorubicin—muscle cancer	0.0271	0.033	CbGbCtD
Ondansetron—CYP3A4—Etoposide—muscle cancer	0.0253	0.0307	CbGbCtD
Ondansetron—CYP3A4—Doxorubicin—muscle cancer	0.0173	0.021	CbGbCtD
Ondansetron—Blindness transient—Methotrexate—muscle cancer	0.00523	0.0316	CcSEcCtD
Ondansetron—Raised liver function tests—Dactinomycin—muscle cancer	0.00478	0.0288	CcSEcCtD
Ondansetron—Electrocardiogram ST segment depression—Doxorubicin—muscle cancer	0.00365	0.022	CcSEcCtD
Ondansetron—Blindness—Vincristine—muscle cancer	0.00356	0.0215	CcSEcCtD
Ondansetron—Anorectal discomfort—Etoposide—muscle cancer	0.00292	0.0176	CcSEcCtD
Ondansetron—Warmth—Doxorubicin—muscle cancer	0.0026	0.0157	CcSEcCtD
Ondansetron—Laryngospasm—Etoposide—muscle cancer	0.00214	0.0129	CcSEcCtD
Ondansetron—Raised liver function tests—Methotrexate—muscle cancer	0.00207	0.0125	CcSEcCtD
Ondansetron—Musculoskeletal pain—Vincristine—muscle cancer	0.00199	0.012	CcSEcCtD
Ondansetron—Cardiovascular disorder—Etoposide—muscle cancer	0.00182	0.011	CcSEcCtD
Ondansetron—Hepatic failure—Dactinomycin—muscle cancer	0.00178	0.0107	CcSEcCtD
Ondansetron—Hepatic failure—Vincristine—muscle cancer	0.00159	0.0096	CcSEcCtD
Ondansetron—Anorectal discomfort—Doxorubicin—muscle cancer	0.00151	0.00914	CcSEcCtD
Ondansetron—Hypoxia—Methotrexate—muscle cancer	0.00151	0.00908	CcSEcCtD
Ondansetron—Blindness—Doxorubicin—muscle cancer	0.0015	0.00902	CcSEcCtD
Ondansetron—Local reaction—Doxorubicin—muscle cancer	0.0015	0.00902	CcSEcCtD
Ondansetron—Liver function test abnormal—Dactinomycin—muscle cancer	0.00148	0.00892	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.00144	0.0087	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Dactinomycin—muscle cancer	0.00144	0.0087	CcSEcCtD
Ondansetron—Liver disorder—Methotrexate—muscle cancer	0.0014	0.00846	CcSEcCtD
Ondansetron—Urinary retention—Vincristine—muscle cancer	0.00136	0.00821	CcSEcCtD
Ondansetron—SLC47A2—renal system—muscle cancer	0.00133	0.122	CbGeAlD
Ondansetron—Swelling—Etoposide—muscle cancer	0.00131	0.00792	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.00129	0.00777	CcSEcCtD
Ondansetron—Redness—Doxorubicin—muscle cancer	0.00123	0.0074	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.00122	0.00738	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Etoposide—muscle cancer	0.0012	0.00722	CcSEcCtD
Ondansetron—Dysuria—Vincristine—muscle cancer	0.00116	0.00697	CcSEcCtD
Ondansetron—Acute coronary syndrome—Vincristine—muscle cancer	0.00109	0.00656	CcSEcCtD
Ondansetron—Myocardial infarction—Vincristine—muscle cancer	0.00108	0.00652	CcSEcCtD
Ondansetron—Feeling hot—Doxorubicin—muscle cancer	0.00105	0.00636	CcSEcCtD
Ondansetron—Erythema multiforme—Dactinomycin—muscle cancer	0.00105	0.00632	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.00104	0.00629	CcSEcCtD
Ondansetron—SLC47A2—tendon—muscle cancer	0.00104	0.0949	CbGeAlD
Ondansetron—Flushing—Dactinomycin—muscle cancer	0.00103	0.0062	CcSEcCtD
Ondansetron—Injection site pain—Doxorubicin—muscle cancer	0.00101	0.00612	CcSEcCtD
Ondansetron—Chills—Dactinomycin—muscle cancer	0.000994	0.006	CcSEcCtD
Ondansetron—Bronchospasm—Etoposide—muscle cancer	0.000985	0.00594	CcSEcCtD
Ondansetron—Neoplasm malignant—Doxorubicin—muscle cancer	0.00097	0.00585	CcSEcCtD
Ondansetron—SLC47A2—vagina—muscle cancer	0.000964	0.0881	CbGeAlD
Ondansetron—Erythema—Dactinomycin—muscle cancer	0.000964	0.00582	CcSEcCtD
Ondansetron—Cardiovascular disorder—Doxorubicin—muscle cancer	0.000942	0.00568	CcSEcCtD
Ondansetron—Cardiac disorder—Vincristine—muscle cancer	0.000918	0.00554	CcSEcCtD
Ondansetron—Ventricular extrasystoles—Doxorubicin—muscle cancer	0.000917	0.00553	CcSEcCtD
Ondansetron—Angiopathy—Vincristine—muscle cancer	0.000898	0.00542	CcSEcCtD
Ondansetron—Ill-defined disorder—Dactinomycin—muscle cancer	0.000895	0.0054	CcSEcCtD
Ondansetron—Mediastinal disorder—Vincristine—muscle cancer	0.000892	0.00538	CcSEcCtD
Ondansetron—SLC47A2—head—muscle cancer	0.000891	0.0814	CbGeAlD
Ondansetron—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.000885	0.00534	CcSEcCtD
Ondansetron—Dyskinesia—Doxorubicin—muscle cancer	0.000881	0.00531	CcSEcCtD
Ondansetron—Acute coronary syndrome—Etoposide—muscle cancer	0.00088	0.00531	CcSEcCtD
Ondansetron—Myocardial infarction—Etoposide—muscle cancer	0.000875	0.00528	CcSEcCtD
Ondansetron—Malaise—Dactinomycin—muscle cancer	0.000869	0.00525	CcSEcCtD
Ondansetron—Hepatobiliary disease—Etoposide—muscle cancer	0.000844	0.00509	CcSEcCtD
Ondansetron—Musculoskeletal pain—Doxorubicin—muscle cancer	0.000838	0.00506	CcSEcCtD
Ondansetron—Hiccups—Doxorubicin—muscle cancer	0.000828	0.00499	CcSEcCtD
Ondansetron—Hepatocellular injury—Doxorubicin—muscle cancer	0.000828	0.00499	CcSEcCtD
Ondansetron—Injection site reaction—Doxorubicin—muscle cancer	0.000823	0.00497	CcSEcCtD
Ondansetron—Discomfort—Dactinomycin—muscle cancer	0.000811	0.00489	CcSEcCtD
Ondansetron—Agitation—Vincristine—muscle cancer	0.000792	0.00478	CcSEcCtD
Ondansetron—Hepatic failure—Methotrexate—muscle cancer	0.000772	0.00466	CcSEcCtD
Ondansetron—Erythema multiforme—Etoposide—muscle cancer	0.000758	0.00457	CcSEcCtD
Ondansetron—Eye disorder—Etoposide—muscle cancer	0.000749	0.00452	CcSEcCtD
Ondansetron—Convulsion—Vincristine—muscle cancer	0.000746	0.0045	CcSEcCtD
Ondansetron—Flushing—Etoposide—muscle cancer	0.000744	0.00449	CcSEcCtD
Ondansetron—Cardiac disorder—Etoposide—muscle cancer	0.000744	0.00449	CcSEcCtD
Ondansetron—Visual disturbance—Methotrexate—muscle cancer	0.000732	0.00442	CcSEcCtD
Ondansetron—Angiopathy—Etoposide—muscle cancer	0.000727	0.00439	CcSEcCtD
Ondansetron—Immune system disorder—Etoposide—muscle cancer	0.000724	0.00437	CcSEcCtD
Ondansetron—Mediastinal disorder—Etoposide—muscle cancer	0.000722	0.00436	CcSEcCtD
Ondansetron—Chills—Etoposide—muscle cancer	0.000719	0.00434	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Methotrexate—muscle cancer	0.000717	0.00433	CcSEcCtD
Ondansetron—Anaphylactic shock—Vincristine—muscle cancer	0.000703	0.00424	CcSEcCtD
Ondansetron—Nervous system disorder—Vincristine—muscle cancer	0.000689	0.00416	CcSEcCtD
Ondansetron—Fatigue—Dactinomycin—muscle cancer	0.000678	0.00409	CcSEcCtD
Ondansetron—Pain—Dactinomycin—muscle cancer	0.000673	0.00406	CcSEcCtD
Ondansetron—Hepatic failure—Doxorubicin—muscle cancer	0.000669	0.00403	CcSEcCtD
Ondansetron—Hypotension—Vincristine—muscle cancer	0.000657	0.00396	CcSEcCtD
Ondansetron—Feeling abnormal—Dactinomycin—muscle cancer	0.000648	0.00391	CcSEcCtD
Ondansetron—Ill-defined disorder—Etoposide—muscle cancer	0.000647	0.00391	CcSEcCtD
Ondansetron—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000643	0.00388	CcSEcCtD
Ondansetron—Liver function test abnormal—Methotrexate—muscle cancer	0.000641	0.00387	CcSEcCtD
Ondansetron—Paraesthesia—Vincristine—muscle cancer	0.000631	0.00381	CcSEcCtD
Ondansetron—Malaise—Etoposide—muscle cancer	0.000629	0.0038	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000625	0.00377	CcSEcCtD
Ondansetron—Abdominal pain—Dactinomycin—muscle cancer	0.000622	0.00375	CcSEcCtD
Ondansetron—Body temperature increased—Dactinomycin—muscle cancer	0.000622	0.00375	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.000621	0.00375	CcSEcCtD
Ondansetron—Loss of consciousness—Etoposide—muscle cancer	0.000613	0.0037	CcSEcCtD
Ondansetron—Cough—Etoposide—muscle cancer	0.000609	0.00367	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Vincristine—muscle cancer	0.000607	0.00366	CcSEcCtD
Ondansetron—Fatigue—Vincristine—muscle cancer	0.000606	0.00366	CcSEcCtD
Ondansetron—Convulsion—Etoposide—muscle cancer	0.000605	0.00365	CcSEcCtD
Ondansetron—Pain—Vincristine—muscle cancer	0.000601	0.00363	CcSEcCtD
Ondansetron—Constipation—Vincristine—muscle cancer	0.000601	0.00363	CcSEcCtD
Ondansetron—Asthma—Methotrexate—muscle cancer	0.0006	0.00362	CcSEcCtD
Ondansetron—Chest pain—Etoposide—muscle cancer	0.000594	0.00358	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00059	0.00356	CcSEcCtD
Ondansetron—Discomfort—Etoposide—muscle cancer	0.000587	0.00354	CcSEcCtD
Ondansetron—Hypersensitivity—Dactinomycin—muscle cancer	0.00058	0.0035	CcSEcCtD
Ondansetron—Gastrointestinal pain—Vincristine—muscle cancer	0.000575	0.00347	CcSEcCtD
Ondansetron—Anaphylactic shock—Etoposide—muscle cancer	0.000569	0.00344	CcSEcCtD
Ondansetron—Asthenia—Dactinomycin—muscle cancer	0.000565	0.00341	CcSEcCtD
Ondansetron—Dysuria—Methotrexate—muscle cancer	0.000561	0.00338	CcSEcCtD
Ondansetron—Tachycardia—Etoposide—muscle cancer	0.000556	0.00335	CcSEcCtD
Ondansetron—Abdominal pain—Vincristine—muscle cancer	0.000556	0.00335	CcSEcCtD
Ondansetron—Body temperature increased—Vincristine—muscle cancer	0.000556	0.00335	CcSEcCtD
Ondansetron—Liver function test abnormal—Doxorubicin—muscle cancer	0.000555	0.00335	CcSEcCtD
Ondansetron—Skin disorder—Etoposide—muscle cancer	0.000553	0.00334	CcSEcCtD
Ondansetron—Hypokalaemia—Doxorubicin—muscle cancer	0.000547	0.0033	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000541	0.00326	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000541	0.00326	CcSEcCtD
Ondansetron—Diarrhoea—Dactinomycin—muscle cancer	0.000538	0.00325	CcSEcCtD
Ondansetron—Drowsiness—Methotrexate—muscle cancer	0.000535	0.00323	CcSEcCtD
Ondansetron—Hypotension—Etoposide—muscle cancer	0.000532	0.00321	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00053	0.0032	CcSEcCtD
Ondansetron—Asthma—Doxorubicin—muscle cancer	0.000519	0.00313	CcSEcCtD
Ondansetron—Hypersensitivity—Vincristine—muscle cancer	0.000518	0.00312	CcSEcCtD
Ondansetron—Paraesthesia—Etoposide—muscle cancer	0.000511	0.00309	CcSEcCtD
Ondansetron—Dyspnoea—Etoposide—muscle cancer	0.000508	0.00306	CcSEcCtD
Ondansetron—Somnolence—Etoposide—muscle cancer	0.000506	0.00305	CcSEcCtD
Ondansetron—Angina pectoris—Doxorubicin—muscle cancer	0.000506	0.00305	CcSEcCtD
Ondansetron—Hepatobiliary disease—Methotrexate—muscle cancer	0.000506	0.00305	CcSEcCtD
Ondansetron—Asthenia—Vincristine—muscle cancer	0.000504	0.00304	CcSEcCtD
Ondansetron—Vomiting—Dactinomycin—muscle cancer	0.0005	0.00302	CcSEcCtD
Ondansetron—Rash—Dactinomycin—muscle cancer	0.000496	0.00299	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Etoposide—muscle cancer	0.000492	0.00297	CcSEcCtD
Ondansetron—Fatigue—Etoposide—muscle cancer	0.000491	0.00296	CcSEcCtD
Ondansetron—Pain—Etoposide—muscle cancer	0.000487	0.00294	CcSEcCtD
Ondansetron—Constipation—Etoposide—muscle cancer	0.000487	0.00294	CcSEcCtD
Ondansetron—Dysuria—Doxorubicin—muscle cancer	0.000486	0.00293	CcSEcCtD
Ondansetron—Haemoglobin—Methotrexate—muscle cancer	0.000483	0.00291	CcSEcCtD
Ondansetron—Diarrhoea—Vincristine—muscle cancer	0.000481	0.0029	CcSEcCtD
Ondansetron—Haemorrhage—Methotrexate—muscle cancer	0.00048	0.0029	CcSEcCtD
Ondansetron—Feeling abnormal—Etoposide—muscle cancer	0.000469	0.00283	CcSEcCtD
Ondansetron—SLC47A1—renal system—muscle cancer	0.000466	0.0426	CbGeAlD
Ondansetron—Gastrointestinal pain—Etoposide—muscle cancer	0.000466	0.00281	CcSEcCtD
Ondansetron—Dizziness—Vincristine—muscle cancer	0.000465	0.0028	CcSEcCtD
Ondansetron—Drowsiness—Doxorubicin—muscle cancer	0.000463	0.00279	CcSEcCtD
Ondansetron—Visual impairment—Methotrexate—muscle cancer	0.000463	0.00279	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000459	0.00277	CcSEcCtD
Ondansetron—Erythema multiforme—Methotrexate—muscle cancer	0.000454	0.00274	CcSEcCtD
Ondansetron—Urticaria—Etoposide—muscle cancer	0.000452	0.00273	CcSEcCtD
Ondansetron—Abdominal pain—Etoposide—muscle cancer	0.00045	0.00272	CcSEcCtD
Ondansetron—Body temperature increased—Etoposide—muscle cancer	0.00045	0.00272	CcSEcCtD
Ondansetron—Urinary tract infection—Doxorubicin—muscle cancer	0.00045	0.00272	CcSEcCtD
Ondansetron—Eye disorder—Methotrexate—muscle cancer	0.000449	0.00271	CcSEcCtD
Ondansetron—Vomiting—Vincristine—muscle cancer	0.000447	0.0027	CcSEcCtD
Ondansetron—Cardiac disorder—Methotrexate—muscle cancer	0.000446	0.00269	CcSEcCtD
Ondansetron—Rash—Vincristine—muscle cancer	0.000443	0.00267	CcSEcCtD
Ondansetron—Dermatitis—Vincristine—muscle cancer	0.000443	0.00267	CcSEcCtD
Ondansetron—Headache—Vincristine—muscle cancer	0.00044	0.00266	CcSEcCtD
Ondansetron—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000438	0.00264	CcSEcCtD
Ondansetron—Angiopathy—Methotrexate—muscle cancer	0.000436	0.00263	CcSEcCtD
Ondansetron—Immune system disorder—Methotrexate—muscle cancer	0.000434	0.00262	CcSEcCtD
Ondansetron—Mediastinal disorder—Methotrexate—muscle cancer	0.000433	0.00261	CcSEcCtD
Ondansetron—Chills—Methotrexate—muscle cancer	0.000431	0.0026	CcSEcCtD
Ondansetron—Bradycardia—Doxorubicin—muscle cancer	0.000423	0.00255	CcSEcCtD
Ondansetron—Hypersensitivity—Etoposide—muscle cancer	0.00042	0.00253	CcSEcCtD
Ondansetron—Erythema—Methotrexate—muscle cancer	0.000418	0.00252	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—muscle cancer	0.000418	0.00252	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—muscle cancer	0.000416	0.00251	CcSEcCtD
Ondansetron—Asthenia—Etoposide—muscle cancer	0.000409	0.00247	CcSEcCtD
Ondansetron—Pruritus—Etoposide—muscle cancer	0.000403	0.00243	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—muscle cancer	0.000401	0.00242	CcSEcCtD
Ondansetron—Vision blurred—Methotrexate—muscle cancer	0.000394	0.00238	CcSEcCtD
Ondansetron—Erythema multiforme—Doxorubicin—muscle cancer	0.000393	0.00237	CcSEcCtD
Ondansetron—Diarrhoea—Etoposide—muscle cancer	0.00039	0.00235	CcSEcCtD
Ondansetron—Eye disorder—Doxorubicin—muscle cancer	0.000389	0.00234	CcSEcCtD
Ondansetron—Ill-defined disorder—Methotrexate—muscle cancer	0.000388	0.00234	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—muscle cancer	0.000386	0.00233	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—muscle cancer	0.000386	0.00233	CcSEcCtD
Ondansetron—Angiopathy—Doxorubicin—muscle cancer	0.000377	0.00228	CcSEcCtD
Ondansetron—Malaise—Methotrexate—muscle cancer	0.000377	0.00227	CcSEcCtD
Ondansetron—Dizziness—Etoposide—muscle cancer	0.000377	0.00227	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—muscle cancer	0.000376	0.00227	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—muscle cancer	0.000375	0.00226	CcSEcCtD
Ondansetron—Chills—Doxorubicin—muscle cancer	0.000373	0.00225	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—muscle cancer	0.000371	0.00224	CcSEcCtD
Ondansetron—Cough—Methotrexate—muscle cancer	0.000365	0.0022	CcSEcCtD
Ondansetron—SLC47A1—tendon—muscle cancer	0.000364	0.0332	CbGeAlD
Ondansetron—Convulsion—Methotrexate—muscle cancer	0.000362	0.00218	CcSEcCtD
Ondansetron—Vomiting—Etoposide—muscle cancer	0.000362	0.00218	CcSEcCtD
Ondansetron—Erythema—Doxorubicin—muscle cancer	0.000362	0.00218	CcSEcCtD
Ondansetron—Rash—Etoposide—muscle cancer	0.000359	0.00217	CcSEcCtD
Ondansetron—Dermatitis—Etoposide—muscle cancer	0.000359	0.00216	CcSEcCtD
Ondansetron—Headache—Etoposide—muscle cancer	0.000357	0.00215	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—muscle cancer	0.000357	0.00215	CcSEcCtD
Ondansetron—Chest pain—Methotrexate—muscle cancer	0.000356	0.00215	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000353	0.00213	CcSEcCtD
Ondansetron—Discomfort—Methotrexate—muscle cancer	0.000352	0.00212	CcSEcCtD
Ondansetron—Anaphylactic shock—Methotrexate—muscle cancer	0.000341	0.00206	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—muscle cancer	0.000341	0.00206	CcSEcCtD
Ondansetron—SLC47A1—vagina—muscle cancer	0.000337	0.0308	CbGeAlD
Ondansetron—Ill-defined disorder—Doxorubicin—muscle cancer	0.000336	0.00203	CcSEcCtD
Ondansetron—Nervous system disorder—Methotrexate—muscle cancer	0.000335	0.00202	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—muscle cancer	0.000333	0.00201	CcSEcCtD
Ondansetron—Skin disorder—Methotrexate—muscle cancer	0.000331	0.002	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—muscle cancer	0.000326	0.00197	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—muscle cancer	0.000325	0.00196	CcSEcCtD
Ondansetron—HTR1A—renal system—muscle cancer	0.000321	0.0293	CbGeAlD
Ondansetron—Palpitations—Doxorubicin—muscle cancer	0.00032	0.00193	CcSEcCtD
Ondansetron—Hypotension—Methotrexate—muscle cancer	0.000319	0.00192	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—muscle cancer	0.000318	0.00192	CcSEcCtD
Ondansetron—HTR3A—head—muscle cancer	0.000317	0.029	CbGeAlD
Ondansetron—Cough—Doxorubicin—muscle cancer	0.000316	0.00191	CcSEcCtD
Ondansetron—Convulsion—Doxorubicin—muscle cancer	0.000314	0.00189	CcSEcCtD
Ondansetron—SLC47A1—head—muscle cancer	0.000312	0.0285	CbGeAlD
Ondansetron—Chest pain—Doxorubicin—muscle cancer	0.000308	0.00186	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—muscle cancer	0.000307	0.00185	CcSEcCtD
Ondansetron—Paraesthesia—Methotrexate—muscle cancer	0.000306	0.00185	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000306	0.00185	CcSEcCtD
Ondansetron—Discomfort—Doxorubicin—muscle cancer	0.000304	0.00184	CcSEcCtD
Ondansetron—Dyspnoea—Methotrexate—muscle cancer	0.000304	0.00183	CcSEcCtD
Ondansetron—Somnolence—Methotrexate—muscle cancer	0.000303	0.00183	CcSEcCtD
Ondansetron—Dry mouth—Doxorubicin—muscle cancer	0.000301	0.00182	CcSEcCtD
Ondansetron—SLC47A1—testis—muscle cancer	0.000301	0.0275	CbGeAlD
Ondansetron—Anaphylactic shock—Doxorubicin—muscle cancer	0.000295	0.00178	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000294	0.00178	CcSEcCtD
Ondansetron—Fatigue—Methotrexate—muscle cancer	0.000294	0.00177	CcSEcCtD
Ondansetron—Pain—Methotrexate—muscle cancer	0.000292	0.00176	CcSEcCtD
Ondansetron—OPRM1—head—muscle cancer	0.000291	0.0266	CbGeAlD
Ondansetron—Shock—Doxorubicin—muscle cancer	0.000291	0.00175	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—muscle cancer	0.00029	0.00175	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—muscle cancer	0.000288	0.00174	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—muscle cancer	0.000287	0.00173	CcSEcCtD
Ondansetron—KCNH2—renal system—muscle cancer	0.000286	0.0261	CbGeAlD
Ondansetron—Feeling abnormal—Methotrexate—muscle cancer	0.000281	0.0017	CcSEcCtD
Ondansetron—OPRM1—testis—muscle cancer	0.000281	0.0257	CbGeAlD
Ondansetron—Gastrointestinal pain—Methotrexate—muscle cancer	0.000279	0.00168	CcSEcCtD
Ondansetron—Hypotension—Doxorubicin—muscle cancer	0.000276	0.00167	CcSEcCtD
Ondansetron—Urticaria—Methotrexate—muscle cancer	0.000271	0.00163	CcSEcCtD
Ondansetron—Abdominal pain—Methotrexate—muscle cancer	0.00027	0.00163	CcSEcCtD
Ondansetron—Body temperature increased—Methotrexate—muscle cancer	0.00027	0.00163	CcSEcCtD
Ondansetron—HTR1B—head—muscle cancer	0.000266	0.0243	CbGeAlD
Ondansetron—Paraesthesia—Doxorubicin—muscle cancer	0.000265	0.0016	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—muscle cancer	0.000263	0.00159	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—muscle cancer	0.000263	0.00158	CcSEcCtD
Ondansetron—KCNH2—cardiac atrium—muscle cancer	0.000256	0.0234	CbGeAlD
Ondansetron—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000255	0.00154	CcSEcCtD
Ondansetron—Fatigue—Doxorubicin—muscle cancer	0.000255	0.00154	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—muscle cancer	0.000253	0.00152	CcSEcCtD
Ondansetron—Pain—Doxorubicin—muscle cancer	0.000253	0.00152	CcSEcCtD
Ondansetron—Hypersensitivity—Methotrexate—muscle cancer	0.000251	0.00152	CcSEcCtD
Ondansetron—CYP1A2—renal system—muscle cancer	0.000245	0.0224	CbGeAlD
Ondansetron—Asthenia—Methotrexate—muscle cancer	0.000245	0.00148	CcSEcCtD
Ondansetron—Feeling abnormal—Doxorubicin—muscle cancer	0.000243	0.00147	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000242	0.00146	CcSEcCtD
Ondansetron—Pruritus—Methotrexate—muscle cancer	0.000241	0.00146	CcSEcCtD
Ondansetron—CYP3A5—renal system—muscle cancer	0.000236	0.0216	CbGeAlD
Ondansetron—Urticaria—Doxorubicin—muscle cancer	0.000235	0.00142	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—muscle cancer	0.000233	0.00141	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—muscle cancer	0.000233	0.00141	CcSEcCtD
Ondansetron—Diarrhoea—Methotrexate—muscle cancer	0.000233	0.00141	CcSEcCtD
Ondansetron—Dizziness—Methotrexate—muscle cancer	0.000226	0.00136	CcSEcCtD
Ondansetron—CYP2E1—renal system—muscle cancer	0.00022	0.0201	CbGeAlD
Ondansetron—Hypersensitivity—Doxorubicin—muscle cancer	0.000218	0.00131	CcSEcCtD
Ondansetron—Vomiting—Methotrexate—muscle cancer	0.000217	0.00131	CcSEcCtD
Ondansetron—KCNH2—bone marrow—muscle cancer	0.000216	0.0197	CbGeAlD
Ondansetron—Rash—Methotrexate—muscle cancer	0.000215	0.0013	CcSEcCtD
Ondansetron—Dermatitis—Methotrexate—muscle cancer	0.000215	0.0013	CcSEcCtD
Ondansetron—HTR1A—head—muscle cancer	0.000215	0.0196	CbGeAlD
Ondansetron—Headache—Methotrexate—muscle cancer	0.000214	0.00129	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—muscle cancer	0.000212	0.00128	CcSEcCtD
Ondansetron—Pruritus—Doxorubicin—muscle cancer	0.000209	0.00126	CcSEcCtD
Ondansetron—KCNH2—vagina—muscle cancer	0.000207	0.0189	CbGeAlD
Ondansetron—Diarrhoea—Doxorubicin—muscle cancer	0.000202	0.00122	CcSEcCtD
Ondansetron—Dizziness—Doxorubicin—muscle cancer	0.000195	0.00118	CcSEcCtD
Ondansetron—KCNH2—head—muscle cancer	0.000191	0.0175	CbGeAlD
Ondansetron—Vomiting—Doxorubicin—muscle cancer	0.000188	0.00113	CcSEcCtD
Ondansetron—Rash—Doxorubicin—muscle cancer	0.000186	0.00112	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—muscle cancer	0.000186	0.00112	CcSEcCtD
Ondansetron—Headache—Doxorubicin—muscle cancer	0.000185	0.00112	CcSEcCtD
Ondansetron—KCNH2—testis—muscle cancer	0.000185	0.0169	CbGeAlD
Ondansetron—CYP3A4—renal system—muscle cancer	0.000177	0.0162	CbGeAlD
Ondansetron—CYP2D6—renal system—muscle cancer	0.000174	0.0159	CbGeAlD
Ondansetron—CYP2E1—tendon—muscle cancer	0.000172	0.0157	CbGeAlD
Ondansetron—CYP3A5—vagina—muscle cancer	0.000171	0.0156	CbGeAlD
Ondansetron—CYP2E1—head—muscle cancer	0.000147	0.0135	CbGeAlD
Ondansetron—CYP2E1—testis—muscle cancer	0.000142	0.013	CbGeAlD
Ondansetron—CYP2D6—head—muscle cancer	0.000117	0.0107	CbGeAlD
Ondansetron—CYP2D6—testis—muscle cancer	0.000113	0.0103	CbGeAlD
